Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H16ClNO2S.ClH |
Molecular Weight | 358.283 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC(=O)[C@@H](N1CCC2=C(C1)C=CS2)C3=CC=CC=C3Cl
InChI
InChIKey=XIHVAFJSGWDBGA-RSAXXLAASA-N
InChI=1S/C16H16ClNO2S.ClH/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14;/h2-5,7,9,15H,6,8,10H2,1H3;1H/t15-;/m0./s1
Molecular Formula | C16H16ClNO2S |
Molecular Weight | 321.822 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. Plavix (clopidogrel bisulfate) is an inhibitor of ADP-induced platelet aggregation acting by direct
inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADPmediated
activation of the glycoprotein GPIIb/IIIa complex. Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that
inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the
binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADPmediated
activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet
aggregation. This action is irreversible. Consequently, platelets exposed to clopidogrel’s active
metabolite are affected for the remainder of their lifespan (about 7 to 10 days). Platelet
aggregation induced by agonists other than ADP is also inhibited by blocking the amplification
of platelet activation by released ADP. Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
6.9 null [pKi] | |||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia.
Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date8.7972479E11 |
|||
Primary | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date8.7963841E11 |
|||
Primary | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date8.7972479E11 |
|||
Preventing | PLAVIX Approved UsePlavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as
follows:
• Recent MI, Recent Stroke or Established Peripheral Arterial Disease
For patients with a history of recent myocardial infarction (MI), recent stroke, or established
peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint
of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
• Acute Coronary Syndrome
-For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave
MI) including patients who are to be managed medically and those who are to be
managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix
has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or
stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or
refractory ischemia. Launch Date8.7972479E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1500 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
15800 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
2520 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
4600 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.521 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02185534 |
75 mg single, oral dose: 75 mg route of administration: oral experiment type: single co-administered: |
CLOPIDOGREL plasma | Homo sapiens population: healthy age: sex: food status: |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3130 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
50600 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
7440 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
9890 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.767 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02185534 |
75 mg single, oral dose: 75 mg route of administration: oral experiment type: single co-administered: |
CLOPIDOGREL plasma | Homo sapiens population: healthy age: sex: food status: |
|
1.09 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT02185534 |
75 mg single, oral dose: 75 mg route of administration: oral experiment type: single co-administered: |
CLOPIDOGREL plasma | Homo sapiens population: healthy age: sex: food status: |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
7.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
75 mg 1 times / day multiple, oral dose: 75 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
7.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22128201 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2% |
unknown, unknown |
CLOPIDOGREL BISULFATE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
600 mg 1 times / day multiple, oral (starting) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
healthy, 20-45 years n = 27 Health Status: healthy Age Group: 20-45 years Sex: M Population Size: 27 Sources: |
Other AEs: Uric acid abnormal... |
1650 mg single, oral Overdose Dose: 1650 mg Route: oral Route: single Dose: 1650 mg Co-administed with:: phenytoin sodium(1400 mg; single) Sources: simvastatin(120 mg; single) |
unknown, 49 years n = 1 Health Status: unknown Age Group: 49 years Sex: M Population Size: 1 Sources: |
|
600 mg 1 times / day multiple, oral (starting) Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 59 years n = 1 Health Status: unhealthy Age Group: 59 years Sex: F Population Size: 1 Sources: |
Disc. AE: Transaminases increased, Fever... AEs leading to discontinuation/dose reduction: Transaminases increased (1 patient) Sources: Fever (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Uric acid abnormal | 5 patients | 600 mg 1 times / day multiple, oral (starting) Highest studied dose Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
healthy, 20-45 years n = 27 Health Status: healthy Age Group: 20-45 years Sex: M Population Size: 27 Sources: |
Fever | 1 patient Disc. AE |
600 mg 1 times / day multiple, oral (starting) Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 59 years n = 1 Health Status: unhealthy Age Group: 59 years Sex: F Population Size: 1 Sources: |
Transaminases increased | 1 patient Disc. AE |
600 mg 1 times / day multiple, oral (starting) Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: |
unhealthy, 59 years n = 1 Health Status: unhealthy Age Group: 59 years Sex: F Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Drug-induced thrombotic microangiopathy: incidence, prevention and management. | 2001 |
|
Benefit of ADP receptor antagonists in atherothrombotic patients: new evidence. | 2001 |
|
Atherothrombosis: a major health burden. | 2001 |
|
Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. | 2001 Apr |
|
Aspirin in patients with coronary artery disease: is it simply irresistible? | 2001 Apr |
|
CURE--clopidogrel's major advance. | 2001 Apr |
|
[Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions]. | 2001 Apr |
|
Regular or "super-aspirins"? A review of thienopyridines or aspirin to prevent stroke. | 2001 Apr |
|
Management of neurological complications of carotid artery stenting. | 2001 Aug |
|
Acute myocardial infarction 2000 treatment. | 2001 Fall |
|
Antithrombotic therapy in cardiac stent patients. | 2001 Jan |
|
Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. | 2001 Jan |
|
[2 platelet inhibitors administered at the same time. Improved prognosis in myocardial infarct?]]. | 2001 Jan 11 |
|
Identification of the platelet ADP receptor targeted by antithrombotic drugs. | 2001 Jan 11 |
|
The role of adenosine 5'-diphosphate receptor blockade in patients with cardiovascular disease. | 2001 Jul |
|
Diffuse alveolar hemorrhage after clopidogrel use. | 2001 Jul |
|
Acute coronary syndrome: are intervention and IIb/IIIa platelet inhibitors epiphenomena? | 2001 Jul-Aug |
|
Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. | 2001 Jun |
|
Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. | 2001 Jun 15 |
|
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. | 2001 Jun 21 |
|
[New platelet inhibitors]. | 2001 Mar |
|
Activation of Gi-coupled receptors releases a tonic state of inhibited platelet aggregation. | 2001 Mar |
|
Initial experience with a newer generation coronary stent. | 2001 Mar |
|
[Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study]. | 2001 Mar 29 |
|
Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist. | 2001 May |
|
Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS). | 2001 May 15 |
|
Coronary stent deployment in situs inversus. | 2001 Nov |
|
Antiplatelet agents for secondary prevention of ischemic stroke. | 2001 Oct |
|
[Clopidogrel in acute coronary syndromes with non-ST elevation. Clinical implications of the CURE trial]. | 2001 Oct |
|
Prevention of venous graft sclerosis with clopidogrel and aspirin combined with a mesh tubing in a dog model of arteriovenous bypass grafting. | 2001 Oct |
|
Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). | 2001 Oct 15 |
|
Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. | 2001 Sep |
|
Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. | 2001 Sep |
|
Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. | 2001 Sep 15 |
|
Clopidogrel versus aspirin after cardiac surgery. | 2001 Sep 25 |
Sample Use Guides
Recent MI, Recent Stroke, or Established Peripheral Arterial Disease
The recommended daily dose of is 75 mg once daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10077233
Incubation of human washed platelets with clopidogrel resulted in a time- (maximum effects after 30 min) and concentration-dependent (IC50 1.9+/-0.3 uM) inhibition of ADP (6 uM)-induced platelet aggregation. Clopidogrel (30 uM) did not inhibit collagen (2.5 ug ml(-1))-, U46619 (1 uM)- or thrombin (0.1 u ml(-1))-induced platelet aggregation.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 23:22:11 UTC 2022
by
admin
on
Fri Dec 16 23:22:11 UTC 2022
|
Record UNII |
426O7XWS6Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL KRKA (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL-TAD (AUTHORIZED: STROKE)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TEVA GENERICS B.V. (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL-HCS (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL KRKA D.D. (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL KRKA (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TEVA PHARMA (AUTHORIZED: STROKE)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TAD (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL-HCS (AUTHORIZED: STROKE)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL DURA (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL QUALIMED (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TEVA GENERICS B.V. (WITHDRAWN: ACUTE CORONARY SYNDROME)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL QUALIMED (WITHDRAWN: STROKE)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL-DURA (WITHDRAWN: STROKE)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL MYLAN (AUTHORIZED: STROKE)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TEVA PHARMA (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TEVA GENERICS B.V. (WITHDRAWN: STROKE)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL KRKA D.D. (AUTHORIZED: STROKE)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL-KRKA (AUTHORIZED: STROKE)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL KRKA D.D. (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL QUALIMED (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TEVA GENERICS B.V. (WITHDRAWN: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL DURA (WITHDRAWN: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
NCI_THESAURUS |
C80483
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TEVA PHARMA (AUTHORIZED: AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL-HCS (AUTHORIZED: ACUTE CORONARY SYNDROME)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL MYLAN (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL TAD (AUTHORIZED: PERIPHERAL VASCULAR DISEASES)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL HCS (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
CLOPIDOGREL MYLAN (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DBSALT002594
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
PRIMARY | |||
|
120202-65-5
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
PRIMARY | |||
|
9798860
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
PRIMARY | |||
|
426O7XWS6Y
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
PRIMARY | |||
|
C96893
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
PRIMARY | |||
|
SUB30779
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
PRIMARY | |||
|
DTXSID40152734
Created by
admin on Fri Dec 16 23:22:11 UTC 2022 , Edited by admin on Fri Dec 16 23:22:11 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |